377 related articles for article (PubMed ID: 25783437)
1. The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis.
Scheltens NM; Galindo-Garre F; Pijnenburg YA; van der Vlies AE; Smits LL; Koene T; Teunissen CE; Barkhof F; Wattjes MP; Scheltens P; van der Flier WM
J Neurol Neurosurg Psychiatry; 2016 Mar; 87(3):235-43. PubMed ID: 25783437
[TBL] [Abstract][Full Text] [Related]
2. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
Susanto TA; Pua EP; Zhou J;
J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
[TBL] [Abstract][Full Text] [Related]
3. Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts.
Scheltens NME; Tijms BM; Koene T; Barkhof F; Teunissen CE; Wolfsgruber S; Wagner M; Kornhuber J; Peters O; Cohn-Sheehy BI; Rabinovici GD; Miller BL; Kramer JH; Scheltens P; van der Flier WM; ; ;
Alzheimers Dement; 2017 Nov; 13(11):1226-1236. PubMed ID: 28427934
[TBL] [Abstract][Full Text] [Related]
4. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
6. CSF lactate levels, τ proteins, cognitive decline: a dynamic relationship in Alzheimer's disease.
Liguori C; Stefani A; Sancesario G; Sancesario GM; Marciani MG; Pierantozzi M
J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):655-9. PubMed ID: 25121572
[TBL] [Abstract][Full Text] [Related]
7. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
[TBL] [Abstract][Full Text] [Related]
8. Statistically Derived Subtypes and Associations with Cerebrospinal Fluid and Genetic Biomarkers in Mild Cognitive Impairment: A Latent Profile Analysis.
Eppig JS; Edmonds EC; Campbell L; Sanderson-Cimino M; Delano-Wood L; Bondi MW;
J Int Neuropsychol Soc; 2017 Aug; 23(7):564-576. PubMed ID: 28578726
[TBL] [Abstract][Full Text] [Related]
9. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative.
Gomar JJ; Bobes-Bascaran MT; Conejero-Goldberg C; Davies P; Goldberg TE;
Arch Gen Psychiatry; 2011 Sep; 68(9):961-9. PubMed ID: 21893661
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.
Visser PJ; Verhey F; Knol DL; Scheltens P; Wahlund LO; Freund-Levi Y; Tsolaki M; Minthon L; Wallin AK; Hampel H; Bürger K; Pirttila T; Soininen H; Rikkert MO; Verbeek MM; Spiru L; Blennow K
Lancet Neurol; 2009 Jul; 8(7):619-27. PubMed ID: 19523877
[TBL] [Abstract][Full Text] [Related]
11. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.
Alves G; Brønnick K; Aarsland D; Blennow K; Zetterberg H; Ballard C; Kurz MW; Andreasson U; Tysnes OB; Larsen JP; Mulugeta E
J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1080-6. PubMed ID: 20547614
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers.
Dong A; Toledo JB; Honnorat N; Doshi J; Varol E; Sotiras A; Wolk D; Trojanowski JQ; Davatzikos C;
Brain; 2017 Mar; 140(3):735-747. PubMed ID: 28003242
[TBL] [Abstract][Full Text] [Related]
13. Disentangling Heterogeneity in Alzheimer's Disease: Two Empirically-Derived Subtypes.
Blanken AE; Dutt S; Li Y; Nation DA;
J Alzheimers Dis; 2019; 70(1):227-239. PubMed ID: 31177226
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients.
Rami L; Fortea J; Bosch B; Solé-Padullés C; Lladó A; Iranzo A; Sánchez-Valle R; Molinuevo JL
J Alzheimers Dis; 2011; 23(2):319-26. PubMed ID: 21098971
[TBL] [Abstract][Full Text] [Related]
15. Markers of Alzheimer's disease in a population attending a memory clinic.
Frisoni GB; Prestia A; Zanetti O; Galluzzi S; Romano M; Cotelli M; Gennarelli M; Binetti G; Bocchio L; Paghera B; Amicucci G; Bonetti M; Benussi L; Ghidoni R; Geroldi C
Alzheimers Dement; 2009 Jul; 5(4):307-17. PubMed ID: 19560101
[TBL] [Abstract][Full Text] [Related]
16. Microbleeds do not affect rate of cognitive decline in Alzheimer disease.
van der Vlies AE; Goos JD; Barkhof F; Scheltens P; van der Flier WM
Neurology; 2012 Aug; 79(8):763-9. PubMed ID: 22875093
[TBL] [Abstract][Full Text] [Related]
17. Biomarker profiles and their relation to clinical variables in mild cognitive impairment.
Schoonenboom SN; Visser PJ; Mulder C; Lindeboom J; Van Elk EJ; Van Kamp GJ; Scheltens PH
Neurocase; 2005 Feb; 11(1):8-13. PubMed ID: 15804919
[TBL] [Abstract][Full Text] [Related]
18. The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment.
Koppara A; Wolfsgruber S; Kleineidam L; Schmidtke K; Frölich L; Kurz A; Schulz S; Hampel H; Heuser I; Peters O; Reischies FM; Jahn H; Luckhaus C; Hüll M; Gertz HJ; Schröder J; Pantel J; Rienhoff O; Rüther E; Henn F; Wiltfang J; Maier W; Jessen F; Kornhuber J; Wagner M
J Alzheimers Dis; 2016; 49(2):547-60. PubMed ID: 26484902
[TBL] [Abstract][Full Text] [Related]
19. Progranulin and Amyloid-β Levels: Relationship to Neuropsychology in Frontotemporal and Alzheimer's Disease.
Körtvélyessy P; Gukasjan A; Sweeney-Reed CM; Heinze HJ; Thurner L; Bittner DM
J Alzheimers Dis; 2015; 46(2):375-80. PubMed ID: 25777512
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination.
Ivanoiu A; Sindic CJ
Neurocase; 2005 Feb; 11(1):32-9. PubMed ID: 15804922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
